Development of Osteoporosis after Hormonal Treatment for Prostate Cancer Patient.
- Author:
Bong Mo SEONG
1
;
Jun CHEON
;
Duck Ki YOON
;
Sung Kun KOH
Author Information
1. Department of Urology, Korea University, College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Osteoporosis;
Hormonal therapy;
Prostate cancer
- MeSH:
Acceleration;
Adenocarcinoma;
Bone Density;
Femur Neck;
Humans;
Hypogonadism;
Male;
Neoplasm Grading;
Osteoporosis*;
Prostate*;
Prostatic Neoplasms*;
Spine
- From:Korean Journal of Urology
1998;39(3):251-258
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Combined androgen blockade(CAB) is often used in the management of advanced adenocarcinoma of the prostate. Recent case reports indicated that hypogonadism from CAB therapy is associated with osteoporosis and related fracture. The effect of CAB on bone mineral density(BMD) has not been adequately studied in men with prostate cancer. In this study, the possibility, frequency and severity of osteoporosis following CAB in prostate cancer patient was investigated. MATERIALS AND METHODS: A total of 19 men with advanced prostate cancer receiving CAB were evaluated for the presence of osteoporosis defined as bone mass 2.5 standard deviation below peak bone mass of young normal men(T-score). The BMB of the femoral neck and lumbar spine were measured. The BMD was then compared to the age-matched control value and reported as the Z-score. BMD measurements were compared to duration of CAB and Gleason score. RESULTS: Osteoporosis occurred in 10 of 15 patients in lumbar spine, and 4 of 18 patients in femoral neck. Osteoporosis was unrelated to the type of the CAB(orchiectomy, or LHRH-agonist). CAB caused a decrease in mean BMD of lumbar spine and femoral neck. There is a negative linear relation between mean BMD and duration of CAB(lumber spine; R2=0.059, Y=-2.368-0.016X, p>0.05, femoral neck; R2=0.089, Y=-1.923-0.020x, p>0.05). There is a statistically significant negative linear relationship between Gleason score and mean T-score of femoral neck(lumbar spine; R2=0.391, Y=-0.08-0.371X, p<0.05, femoral neck; R2=0.517, Y=0.855-0.450x, p<0.005). CONCLUSIONS: Our study provide evidence for acceleration of osteoporosis among men whose prostate cancers were treated with CAB. This study indicates a need for bone mineral density determination at the onset of CAB and at periodic intervals there after to begin appropriate therapy, undefined at this point, for prevention of osteoporosis and its complications aggravated by this therapy.
